Addex Therapeutics Ltd Logo

Addex Therapeutics Ltd

ISIN: CH0029850754 | Ticker: ADXN | LEI: 89450068Y9KVP2MQGH86
Sector: Health CareSub-Industry: Pharmaceuticals
Country: Switzerland

About Addex Therapeutics Ltd

Company Description

Addex Therapeutics is a clinical-stage pharmaceutical company focused on the development and commercialization of an emerging class of novel orally available small molecule drugs known as allosteric modulators for neurological disorders.

Allosteric modulators offer several potential advantages over conventional non-allosteric molecules and may offer an improved therapeutic approach to conventional "orthosteric" small molecule or biological drugs. Addex's allosteric modulator drug discovery platform targets receptors and other proteins that are recognized as essential for therapeutic intervention.

Addex's lead drug candidate, dipraglurant (mGlu5 negative allosteric modulator or NAM), is in a pivotal registration clinical trial for Parkinson’s disease levodopa induced dyskinesia (PD-LID).

Year founded

2002

Served area

Worldwide

Headcount

28

Headquarters

Chemin des Aulx 12, 1228 Plan-les-Ouates – Switzerland

Insider Trades

Date Trading entity / Person Association Trade type Volume
27.11.23 None Executive member Buy CHF 301,345.00
27.11.23 None Executive member Buy CHF 53,760.00
27.11.23 None Executive member Buy CHF 45,450.00
27.11.23 None Non-Executive member Buy CHF 44,856.00
27.11.23 None Non-Executive member Buy CHF 24,423.00
27.11.23 None Executive member Buy CHF 5,487.00
27.11.23 None Non-Executive member Buy CHF 3,927.00
27.11.23 None Executive member Buy CHF 2,150.00

Capital markets information

ISIN

CH0029850754

LEI

89450068Y9KVP2MQGH86

Sector

Health Care

Industry Group

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Pharmaceuticals

Sub-Industry

Pharmaceuticals

Listed Stock Exchange

SIX Swiss Exchange

Contact Investor Relations department

Stay up to date

Keep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.